RenalPro
Pre-clinical- Indications
- Acute Kidney Injury, Cardiac Surgery Associated Acute Kidney Injury, Contrast-Associated Acute Kidney Injury
Company intelligence / Profile preview
CardioRenal Systems has developed RenalGuard Therapy, a device-based solution for preventing acute kidney injury (AKI), especially in patients undergoing cardiac surgery or exposed to contrast agents. The system uses real-time urine output monitoring and IV infusion to optimize hydration and maximize urine output. Clinical trials have shown a 52% reduction in AKI compared to standard of care, with positive results from a 220-patient randomized controlled trial. The technology has received FDA Breakthrough Device Designation and CE approval, with growing adoption across Europe and the Middle East[1][3][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CardioRenal Systems.